0001655759-24-000040.txt : 20240321 0001655759-24-000040.hdr.sgml : 20240321 20240321161502 ACCESSION NUMBER: 0001655759-24-000040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240318 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Berkowitz Noah CENTRAL INDEX KEY: 0001369900 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38672 FILM NUMBER: 24771528 MAIL ADDRESS: STREET 1: 6 CAMUS DRIVE CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARVINAS, INC. CENTRAL INDEX KEY: 0001655759 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472566120 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 WINCHESTER AVE STREET 2: 5 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-535-1456 MAIL ADDRESS: STREET 1: 395 WINCHESTER AVE STREET 2: 5 SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 FORMER COMPANY: FORMER CONFORMED NAME: ARVINAS INC. DATE OF NAME CHANGE: 20181001 FORMER COMPANY: FORMER CONFORMED NAME: ARVINAS HOLDING COMPANY, LLC DATE OF NAME CHANGE: 20151015 4 1 wk-form4_1711052087.xml FORM 4 X0508 4 2024-03-18 0 0001655759 ARVINAS, INC. ARVN 0001369900 Berkowitz Noah C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVE. NEW HAVEN CT 06511 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-03-18 4 A 0 63452 0 A 63452 D Stock Option (right to buy) 42.60 2024-03-18 4 A 0 93879 0 A 2034-03-17 Common Stock 93879 93879 D The restricted stock units (each, an "RSU") were granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The option was granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on March 18, 2025, with the remainder of the shares vesting in equal monthly installments following March 18, 2025 through March 18, 2028. /s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz 2024-03-21